Compare Heron Therapeutics Inc (HRTX) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Palantir Technologies Inc — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Palantir Technologies Inc trades at $200.02 (market cap $466.48B). The key difference: Palantir Technologies Inc is far larger — about 6300.4× Heron Therapeutics Inc's market cap, and Palantir Technologies Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Palantir Technologies Inc for 78 Days on average.
| HRTX | PLTR | |
|---|---|---|
Market Cap | $74.04M | $466.48B |
Volume | 3,668,095 | 15,675,589 |
Sector | Health | Technology |
52-Week High | $1.49 | $207.18 |
52-Week Low | $0.27 | $107.27 |
Typical Hold Time | 35 Days | 78 Days |
Enterprise Value | $180.78M | $457.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Palantir (PLTR) trades at $198.78, up 3.48% with strong bullish technical signals and consecutive earnings beats. The stock shows robust revenue growth from $1.9B in 2022 to $4.48B in 2025, with net income turning positive to $1.63B. Recent partnership with Armada for sovereign AI infrastructure and positive analyst coverage support momentum, though valuation ratios remain elevated.
Outlook remains positive with accelerating AI adoption and strong fundamentals, but high P/E of 165.91 and P/S of 81.08 present valuation risks. Analyst consensus price target of $185.58 suggests potential downside, while growth trajectory and institutional bullish sentiment offer upside potential amid competitive and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
